Volvariella volvacea, commonly referred to as paddy straw mushroom, is renowned for its remarkable medicinal and nutritional properties. This mushroom, part of the family Pluteaceae, thrives in tropical and subtropical regions and is highly esteemed for its distinctive flavor and substantial health benefits. The fruiting body of V. volvacea is a rich source of bioactive compounds, including antioxidant enzymes, terpenes, polypeptides, sugars, phenolics, and flavonoids. These compounds exhibit an extensive range of therapeutic activities such as anti-tumor, anti-microbial, antioxidant, anti-malarial, anti-cancer, anti-inflammatory, and anti-allergic effects. Nutritionally, V. volvacea is an excellent source of carbohydrates, proteins, fibers, ascorbic acid, and essential minerals. It also boasts a comprehensive profile of amino acids, including valine, arginine, glutamine, serine, aspartic acid, leucine, isoleucine, tyrosine, asparagine, lysine, cystine, proline, glycine, tryptophan, methionine, phenylalanine, threonine, and histidine. This review emphasizes the significant medicinal and nutritional potential of V. volvacea, advocating its inclusion as a functional food to enhance human health and well-being. By highlighting its diverse bioactive compounds and therapeutic benefits, this review aims to foster greater recognition and utilization of paddy straw mushroom in both dietary and medicinal applications.

Streptococcus pneumoniae is a notorious Gram-positive pathogen present asymptomatically in the nasophayrnx of humans. According to the World Health Organization (W.H.O), pneumococcus causes approximately one million deaths yearly. Antibiotic resistance in S. pneumoniae is raising considerable concern around the world. There is an immediate need to address the major issues that have arisen as a result of persistent infections caused by S. pneumoniae. In the present study, subtractive proteomics was used in which the entire proteome of the pathogen consisting of 1947 proteins is effectively decreased to a finite number of possible targets. Various kinds of bioinformatics tools and software were applied for the discovery of novel inhibitors. The CD-HIT analysis revealed 1887 non-redundant sequences from the entire proteome. These non-redundant proteins were submitted to the BLASTp against the human proteome and 1423 proteins were screened as non-homologous. Further, databases of essential genes (DEGG) and J browser identified almost 171 essential proteins. Moreover, non-homologous, essential proteins were subjected in KEGG Pathway Database which shortlisted six unique proteins. In addition, the subcellular localization of these unique proteins was checked and cytoplasmic proteins were chosen for the druggability analysis, which resulted in three proteins, namely DNA binding response regulator (SPD_1085), UDP-N-acetylmuramate—L-alanine Ligase (SPD_1349) and RNA polymerase sigma factor (SPD_0958), which can act as a promising potent drug candidate to limit the toxicity caused by S. pneumoniae. The 3D structures of these proteins were predicted by Swiss Model, utilizing the homology modeling approach. Later, molecular docking by PyRx software 0.8 version was used to screen a library of phytochemicals retrieved from PubChem and ZINC databases and already approved drugs from DrugBank database against novel druggable targets to check their binding affinity with receptor proteins. The top two molecules from each receptor protein were selected based on the binding affinity, RMSD value, and the highest conformation. Finally, the absorption, distribution, metabolism, excretion, and toxicity (ADMET) analyses were carried out by utilizing the SWISS ADME and Protox tools. This research supported the discovery of cost-effective drugs against S. pneumoniae. However, more in vivo/in vitro research should be conducted on these targets to investigate their pharmacological efficacy and their function as efficient inhibitors.